Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...

A study by Washington University School of Medicine and the VA St. Louis Health Care System has found that GLP-1 drugs can have both health benefits and risks, including reduced risks of ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have other untapped potentials to reduce health risks.

The U.S. Food and Drug Administration (FDA) has declared an end to shortages of the GLP-1 drugs Mounjaro and Zepbound, a move that means online pharmacies will have to stop selling compounded ...

Paying attention to the exact order in which you eat your food may give you an additional edge in optimising your health.

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.